Analysts at KeyCorp initiated coverage on shares of Rapid Micro Biosystems (NASDAQ:RPID - Get Free Report) in a report released on Wednesday, Marketbeat reports. The brokerage set an "overweight" rating and a $8.00 price target on the stock. KeyCorp's price objective would suggest a potential upside of 129.89% from the company's previous close. KeyCorp also issued estimates for Rapid Micro Biosystems' FY2024 earnings at ($1.10) EPS, Q1 2025 earnings at ($0.27) EPS, Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($0.97) EPS and FY2026 earnings at ($0.82) EPS.
Rapid Micro Biosystems Stock Performance
Rapid Micro Biosystems stock traded down $0.09 on Wednesday, reaching $3.48. The company's stock had a trading volume of 551,651 shares, compared to its average volume of 426,841. The company has a market cap of $149.74 million, a price-to-earnings ratio of -3.11 and a beta of 1.26. The business's fifty day moving average price is $1.50 and its 200 day moving average price is $1.13. Rapid Micro Biosystems has a twelve month low of $0.58 and a twelve month high of $3.75.
Hedge Funds Weigh In On Rapid Micro Biosystems
An institutional investor recently raised its position in Rapid Micro Biosystems stock. Renaissance Technologies LLC increased its position in shares of Rapid Micro Biosystems, Inc. (NASDAQ:RPID - Free Report) by 122.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 183,087 shares of the company's stock after acquiring an additional 100,942 shares during the quarter. Renaissance Technologies LLC owned about 0.43% of Rapid Micro Biosystems worth $165,000 at the end of the most recent quarter. Institutional investors own 52.60% of the company's stock.
Rapid Micro Biosystems Company Profile
(
Get Free Report)
Rapid Micro Biosystems, Inc, a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services.
Read More
Before you consider Rapid Micro Biosystems, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapid Micro Biosystems wasn't on the list.
While Rapid Micro Biosystems currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
